The metamorphosis of hydromorphone

Gary M. Reisfield, MD; George R. Wilson, MD

doi:10.5055/jom.2005.0033

Authors

Gary M. Reisfield, MD
George R. Wilson, MD

DOI:

https://doi.org/10.5055/jom.2005.0033

Keywords:

-

Abstract

-

Author Biographies

Gary M. Reisfield, MD

Assistant Professor and Director, Division of Palliative Medicine, Department of Community Health and Family Medicine, University of Florida Health Science Center–Jacksonville, Jacksonville, Florida.

George R. Wilson, MD

Associate Professor and Chairman, Department of Community Health and Family Medicine, University of Florida Health Science Center–Jacksonville, Jacksonville, Florida.

References

Sarhill N, Walsh D, Nelson KA: Hydromorphone: Pharmacology and clinical applications in cancer patients. Support Care Cancer. 2001; 9: 84-96.

Booth M: Opium: A history. New York: St. Martin’s Press, 1996: 201.

Meier B: Pain Killer: A Wonder Drug’s Trail of Addiction and Death. Emmaus, PA: Rodale, 2003: 88.

Eddy NB: Dilaudid (hydromorphinone hydrochloride). JAMA. 1933; 100(13): 1032-1033.

David NA: Dilaudid and morphine effects on basal metabolism and other body functions. JAMA. 1934; 103(7): 474-478.

Nathanson IT, Daland EM: The use of dilaudid in treating patients with cancer. N Engl J Med. 1935;213(16):741-746.

Stroud CM: The use of Dilaudid in the pain of cancer. JAMA. 1934; 103(19): 1421-1424.

Council on Pharmacy and Chemistry. Preliminary reports of the council. Dilaudid. JAMA. 1933; 100(13): 1031-1032.

Eddy NB, May EL: The search for a better analgesic. Science. 1973; 181: 407-414.

Hanna C, Mazuzan JE, Abajian J: An evaluation of dihydromorphinone in treating postoperative pain. Anesth Analg. 1962; 41(6): 755-761.

Goldman AH: Elvis. New York: McGraw-Hill, 1981: 556-560.

Szasz T: Therapeutic state—Unequal justice for all. Available online at http://www.fee.org. Accessed 11/4/04.

Kane: A tiny yellow piece of heaven. Hydromorphone (Dilaudid). Available online at http://www.erowid.org/experiences/exp.php?ID=21421. Accessed 10/11/04.

ILLadvised: I can see why it is so addictive. Hydromorphone. Available online at http://www.erowid.org/experiences/exp.php?ID=21315. Accessed 10/11/04.

McBride DC, McCoy CB, Rivers JE, et al.: Dilaudid use: Trends and characteristics of users. Chem Depend. 1980; 4(2): 85-100.

Lindberg DK: A word of warning. Marked increase in hydromorphone (Dilaudid) addiction. J Florida Med Assoc. 1978; 65(10): 822.

Lindberg DK: How the addict gets his prescription. J Florida Med Assoc. 1984; 71(4): 240-242

Drugs and chemicals of concern. Hydromorphone. US Department of Justice, Drug Enforcement Administration, Diversion Control Program. Available online at http://www.deadiversion.usdoj.gov/drugs_concern/hydromorphone.htm. Accessed 10/7/04.

Narcanon Southern California. Available online at http://www.heroinaddiction2.com/dilaudid.htm19.

Drug Intelligence Brief. Oxycontin: Pharmaceutical diversion, March 2002. Available online at http://www.usdoj.gov/dea/pubs/intel/02017/02017p.html. Accessed 3/22/05.

Gilson AM, Ryan KM, Joranson DE, et al.: A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997-2002. J Pain Symptom Manage. 2004; 28(2): 176-188.

Lavoie LO: Generic short acting hydromorphone vs. Dilaudid. College Newsletter: A Publication of the College of Physicians and Surgeons of Saskatchewan. 2004; 20(57): 8-9.

Joranson DE, Ryan KM, Gilson AM, et al.: Trends in medical use and abuse of opioid analgesics. JAMA. 2000; 283(13): 1710-1714.

Scholz J, Steinfath M, Koch C, et al.: The pharmacologic basis of potoperative pain therapy. Epidural opioid administration. Anaesthetist. 1997; 46 (Suppl 3):S154-S158.

Anderson VC, Cooke B, Burchiel KJ: Intrathecal hydromorphone for chronic nonmalignant pain: A retrospective study. Pain Medicine. 2001; 2(4): 287-297.

Sarhill N, Walsh D, Khawam E, et al.: Nebulized hydromorphone for dyspnea in hospice care of advanced cancer. Am J Hosp Palliat Care. 2000; 17(6): 389-391.

Rudy AC, Coda BA, Archer SM, et al.: A multiple-dose phase I study of intranasal hydromorphone hydrochloride in health volunteers. Anesth Analg. 2004; 99(5): 1379-1386.

Babul N, Darke AC: Putative role of hydromorphone metabolites in myoclonus (Letter). Pain. 1992; 51(2): 260-261.

Palladone XL product monograph (Canadian-approved label). Purdue Pharma, LP, 6/16/99, revised 2/28/02.

Smith MT: Neuroexcitatory effects of morphine and hydromorphone: Evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol. 2000; 27: 524-528.

Wright AWE, Mather LE, Smith MT: Hydromorphone-3-glucuronide a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide. Life Sci. 2001; 69: 409-420.

Babul N, Darke AC, Hagen N: Hydromorphone metabolite accumulation in renal failure (letter). J Pain Symptom Manage 1995; 10(3): 184-186.

Sarhill N, Walsh D, Nelson KA: Hydromorphone: Pharmacology and clinical applications in cancer patients. Support Care Cancer. 2001; 9: 84-96.

Hutchinson MR, Menelaou A, Foster DJR, et al.: CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2003; 57(3): 287-297.

Otton SV, Schadel M, Cheung SW, et al.: CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther. 1993; 54(5): 463-472.

Armstrong SC, Cozza KL: Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: Theory and clinical reality, part I. Psychosomatics. 2003; 44(2): 167-171.

DeStoutz ND, Bruera E, Suarez-Almazor M: Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage. 1995; 10(5): 378-384.

Lee MA, Leng ME, Tiernan EJ: Retrospective study of the use of Hydromorphone in palliative care patients with normal and abnormal urea and creatinine. Palliat Med. 2001; 15(1): 26-34.

Dean M: Opioids in renal failure and dialysis patients. J Pain Symptom Manage. 2004; 28(5): 497-504.

Jasinski DR, Pevnick JS, Clark SC, et al.: Therapeutic usefulness of propoxyphene napsylate in narcotic addiction. Arch Gen Psychiatry. 1977; 34(2): 227-233.

Hill, JL, Zacny JP: Comparing the subjective, psychomotor, and physiological effects of intravenous hydromorphone and morphine in healthy volunteers. Psychopharmacology. 2000; 152: 31-39.

Quinn DI, Wodak A, Day RO: Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users. Clin Pharmacokin. 1997; 33(5): 344-400.

Ferrell B, Wisdom C, Wenzl C, et al.: Effects of controlledrelease morphine on quality of life for cancer pain. Oncol Nurs Forum. 1989; 16: 521-526.

Palangio M, Northfelt DW, Portenoy RK, et al.: Dose conversion and titration with a novel, once-daily OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain. J Pain Symptom Manage. 2002; 23(5): 355-368.

Angst MS, Drover DR, Lotsch J, et al.: Pharmacodynamics of orally administered sustained-release hydromorphone in humans. Anesthesiology. 2001; 94: 63-73.

Hays H, Hagen N, Thirwell M, et al.: Comparative clinical efficacy and safety of immediate release and controlled release hydromorphone for chronic severe cancer pain. Cancer. 1994; 74(6): 1808-1816.

Bruera E, Sloan P, Mount B, et al.: A randomized, doubleblind, double dummy, crossover trial comparing the safety and efficacy of oral sustained-release hydromorphone with immediate-release Hydromorphone in patients with cancer pain. Canadian Palliative Care Clinical Trials Group. J Clin Oncol. 1996; 14(5): 1713-1717.

Weinstein SM, Grosset AB, Roberts MS, et al.: Two double blind randomized trials of once-a-day controlled release oral hydromorphone (Palladone XL) compared to immediate release hydromorphone dosed QID. American Pain Society Annual Meeting poster #645. Available online at http://www.ampainsoc.org/abstract/1999/data/148/index.html. Accessed 10/25/04.

Hagen NA, Babul N: Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone formulation in the treatment of cancer pain. Cancer. 1997; 79(7): 1428-1437.

FDA talk paper. FDA approves new extended release pain medication: Agency works with sponsor to develop an effective plan to reduce inappropriate use. Available online at http://www.fda.gov/bbs/topics/ANSWERS/2004/AN01315.html. Accessed 10/11/04.

Purdue begins shipment of Palladone (hydromorphone HCl extended-release) capsules (CII). Available online at http://www.purduepharma.com/pressroom/news/20050107-02.htm. Accessed 1/24/05.

Purdue Pharma, LP: Palladone package insert.